Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings (NASDAQ: BREA) , an Ireland-based multi-club ownership company, reported that its majority-owned club S.S. Juve Stabia has seen a 245% increase in valuation during the 2024–25 Serie B season, reaching US$32 million. Brera acquired the team following its promotion from Serie C, and it advanced to the Serie A promotion playoffs semifinals. As the first MCO listed on Nasdaq, Brera allows retail investors access to the growing "sports as an asset class" trend. The company's model contrasts with celebrity-driven club ownership like Ryan Reynolds and Rob McElhenney's investment in lower-division Wrexham.

To view the full press release, visit https://ibn.fm/nHNlf

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Brera Holdings PLC (NASDAQ: BREA), closed Tuesday's trading session at $8.55, up 12.3522%, on 19 volume. The average volume for the last 3 months is 17,560 and the stock's 52-week low/high is $4.999/$19.5.

Recent News

• Brera Holdings PLC (NASDAQ: BREA) - InvestorNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Highlights Juve Stabia's Surge in Value Amid Growing U.S. Interest in European Soccer
• InvestorNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Attracts Family Office Investors as Juve Stabia Valuation Soars 245%
• Brera Holdings PLC (NASDAQ: BREA) Finalizes Majority Stake Acquisition in SS Juve Stabia as Club Value Soars 245%

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected to be immediately accretive to revenue and EBITDA.

Cohen, serving the Sarasota-Bradenton area in Florida, specializes in treatments, including ketamine and TMS, for mood disorders, PTSD, and suicidal depression.

HOPE Therapeutics is expanding toward a target of 30 clinics with a $100 million run rate by the end of 2025.

NRx Pharmaceuticals (NASDAQ: NRXP) , a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49% stake in Cohen and Associates, LLC, a respected neuropsychiatry clinic based in western Florida ( https://ibn.fm/geIxF ).

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

• NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
• NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
• Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Tuesday's trading session at $3.38, up 0.2967359%, on 431 volume. The average volume for the last 3 months is 273,380 and the stock's 52-week low/high is $1.1/$6.01.

Recent News

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) - NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic
• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100
• BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

BluSky AI Inc. (OTC: BSAI)

The QualityStocks Daily Newsletter would like to spotlight BluSky AI Inc. (OTC: BSAI).

BluSky AI (OTC: BSAI) , a developer of modular AI data center infrastructure, announced the acquisition of its first operational site in Central, Utah, securing 9.3 MW of grid-connected power through an agreement with Digital Asset Management, LLC. In exchange for exclusive power rights, BluSky AI issued 20 million shares of restricted stock. The company also signed a ground lease with Wild Mustang Ventures LLC for 51.6 acres, with an option to purchase. These agreements position BluSky AI to launch and scale its flagship data center project with long-term power stability and operational control.

To view the full press release, visit https://ibn.fm/3LA9h

BluSky AI Inc. (OTC: BSAI) is pioneering the next generation of AI infrastructure through modular, rapidly deployable data centers that meet the escalating compute demands of artificial intelligence, machine learning, and high-performance computing. The company’s mission is to empower AI innovators by eliminating infrastructure bottlenecks and accelerating time-to-compute with energy-efficient, scalable solutions.

Rather than betting on individual AI applications, BluSky AI addresses the universal need for compute power—positioning itself as a foundational layer in the AI revolution. Its infrastructure-first approach enables clients to focus on innovation while the company delivers the critical backbone powering tomorrow’s breakthroughs.

BluSky AI is headquartered in Salt Lake City, Utah.

Products

BluSky AI’s core offering is its SkyMod series of modular data centers—pre-assembled, scalable compute units designed specifically for AI workloads. The flagship SkyMod One delivers 1 MW of compute power in a compact 1,400-square-foot footprint, while the SkyMod XL offers 1.7 MW in 3,000 square feet. These units are fully assembled off-site, tested, and shipped ready for plug-and-play deployment either on BluSky-owned land or client facilities.

SkyMod modules integrate NVIDIA GPUs and are optimized for high-density AI applications such as generative AI, large language models, inference engines, and scientific computing. Built for rapid scaling and high efficiency, each system includes advanced cooling, secure infrastructure, and dynamic workload balancing to support evolving client needs.

The company’s data centers are engineered for sustainability, incorporating renewable energy sources like solar, wind, and geothermal where available. By deploying on powered land assets, BluSky AI shortens lead times and lowers costs, creating a fast, flexible alternative to traditional monolithic data centers.

Market Opportunity

The global data center market was valued at $347.6 billion in 2024 and is projected to reach $652.0 billion by 2030, growing at a CAGR of 11.2%, driven by the rapid expansion of AI, machine learning, and IoT adoption, according to Grand View Research. As enterprises demand faster, more scalable compute solutions, modular infrastructure like BluSky AI’s SkyMod series offers a compelling alternative to legacy data center models.

With North America accounting for over 40% of the global market and the U.S. expected to grow at a 10.7% CAGR from 2025 to 2030, BluSky AI is well-positioned to capture demand for AI-optimized infrastructure that can be deployed rapidly and cost-effectively. By focusing on GPU-centric, modular deployments tied to energy infrastructure, the company addresses a growing gap between compute demand and deployment speed in the AI era.

Leadership Team

Trent D’Ambrosio, Chief Executive Officer, is a seasoned executive with a track record in telecommunications, hedge fund management, and natural resource development. He previously sold the first transatlantic fiber cable, built a successful gold mining company, and now leads BluSky AI with a vision to revolutionize AI infrastructure through strategic energy integration and rapid deployment.

Julien Bedard, Chief Technology Officer, is a pioneering technologist known for launching the first Bitcoin escrow and anti-fraud service. At BluSky AI, he oversees cloud architecture, cybersecurity, infrastructure automation, and the development of AI-native data center technology, ensuring scalability and resilience across deployments.

Dan Gay, Chief Operating Officer, has Fortune 500 executive leadership in telecom, technology, and energy, as well as start-up experience with finance and blockchain companies. At MCI and Qwest, he launched new service and sales centers, and directed National Account Sales. He has been a successful CMO in brand creation, product development, partnerships, and revenue generation programs to expand company awareness, sales, and revenue.

BluSky AI Inc. (OTC: BSAI), closed Tuesday's trading session at $2.8, up 21.7391%, on 838 volume. The average volume for the last 3 months is 4,050 and the stock's 52-week low/high is $0.118/$5.49.

Recent News

• BluSky AI Inc. (OTC: BSAI) - AINewsBreaks - BluSky AI Inc. (OTC: BSAI) Secures 9.3 MW Power and Land for Flagship Utah Data Center
• BlueSky AI Inc. (BSAI) Expands Market Presence with Strategic Milestones in AI Infrastructure
• InvestorNewsBreaks - BluSky AI Inc. (OTC: BSAI) Taps IBN to Lead Communications Strategy for Modular AI Data Center Push 

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. "HeartBeam's vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection, but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking," reads a recent article. "As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus on high-margin, recurring revenue."

To view the full article, visit https://ibn.fm/PN36l

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. The company is creating the first ever cable-free synthesized 12-lead ECG platform designed to give patients the ability to record their symptoms the moment they occur, wherever they are. By providing synthesized, 12-lead ECG data, physicians can quickly assess the symptoms and ensure patients get the care they need in a timely manner. It also eliminates the need for wires, complex setup, or clinical staff, thus allowing synthesized 12-lead ECG signals to be accessible outside of a medical setting.

HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection but also unlocks future capabilities in ischemia detection, AI-assisted analysis, and longitudinal cardiac trend tracking.

The HeartBeam System is now FDA cleared for arrhythmia assessment, following foundational 510(k) clearance granted in December 2024. The company submitted a 510(k) application for its 12-lead ECG synthesis software in January 2025 for arrhythmia assessment. As it approaches commercialization, HeartBeam is executing a multi-phase go-to-market strategy with initial U.S. rollout plans and a focus on high-margin, recurring revenue.

The company is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship product is a credit card-sized, cable-free device designed to capture ECG signals in three non-coplanar directions and transform them into synthesized 12-lead ECGs. This novel form factor integrates a smartphone app, cloud connectivity, and a physician portal, enabling patients to record cardiac events at the moment symptoms occur and physicians to assess and triage in near real time.

The device is supported by an expanding software ecosystem. A key component of this is HeartBeam’s proprietary 12-lead ECG synthesis software, which met its clinical endpoint in the VALID-ECG pivotal study with 93.4% manual diagnostic agreement for arrhythmia assessment. This software is currently under FDA review and is designed to deliver clinical-grade arrhythmia diagnostic capabilities outside of traditional healthcare environments.

In April 2025, HeartBeam announced a strategic partnership with AccurKardia to incorporate its FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s offering. This integration is expected to enhance automated rhythm interpretation, streamline physician workflows, and improve diagnostic speed and accuracy.

Additional form factors are under development, including an on-demand synthesized 12-lead patch with issued patents, intended to serve the extended-wear market segment. These complementary offerings are intended to support chronic disease management and continuous monitoring applications, broadening HeartBeam’s total product ecosystem in the future.

Market Opportunity

HeartBeam is targeting large and growing segments within the $20 billion+ global cardiac monitoring and diagnostics market. According to the company’s own materials, the U.S. concierge care segment alone represents a $500 million serviceable addressable market (SAM), comprising approximately 1.5 million patients—500,000 of whom are at elevated cardiac risk. This initial focus provides a strategic entry point for cash-pay and early adoption.

Expanding beyond this niche, HeartBeam identifies a $1.3 billion to $2.6 billion annual opportunity in the broader U.S. direct patient pay market, driven by more than 2.6 million high-income individuals aged 35–74 with elevated cardiac risk. For comparison, more than 2.5 million Oura rings and over 3 million AliveCor Kardia devices have been sold, demonstrating strong consumer willingness to adopt personal cardiac technologies.

HeartBeam’s long-term opportunity is significantly larger. The company estimates that over 20 million people in the U.S. are at high risk for myocardial infarction (MI), representing a total addressable market nearly 40 times greater than the concierge segment. Additionally, the company’s on-demand 12-lead patch aims to capture market share in the extended wear and mobile cardiac telemetry (MCOT) space, competing with incumbents like iRhythm, Boston Scientific, Philips, and Baxter.

Leadership Team

Robert P. Eno, Chief Executive Officer and Director, brings over 30 years of experience launching disruptive medical technologies and leading commercialization efforts. He has held executive roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular, and holds an MBA and BA from Stanford University.

Branislav Vajdic, PhD, President and Founder, is a seasoned innovator with over three decades of experience in technology and device development. He co-invented flash memory at Intel and led engineering teams responsible for the Pentium processor series. He previously served as CEO of NewCardio and holds a PhD in Electrical Engineering from the University of Minnesota.

Timothy Cruickshank, Chief Financial Officer, has over 15 years of experience in financial and strategic leadership roles. Formerly CFO at ImpediMed, he transformed the company into a SaaS-driven model. He holds an MBA from Keller Graduate School and a BS in Accounting from Syracuse University.

Peter J. Fitzgerald, MD, PhD, Chief Medical Officer, is a Stanford professor emeritus and interventional cardiologist with leadership in over 175 clinical trials and 24 medical startups. He co-founded TriVentures and has advised the FDA for over 20 years.

Ken Persen, Chief Technology Officer, has more than 25 years of experience in cardiac and digital health technology, including founding LIVMOR and leadership roles at Guidant and Cameron Health. He specializes in system design and product engineering for connected cardiac solutions.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $1.32, up 1.5385%, on 20 volume. The average volume for the last 3 months is 155,226 and the stock's 52-week low/high is $1.17/$3.48.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - BioMedNewsBreaks - Why HeartBeam Inc. (NASDAQ: BEAT) Is 'One to Watch'
• InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) to Present at iAccess Alpha Virtual Summer Conference 
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company's precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi's approach represents a potential breakthrough in addressing critical unmet needs. The company's platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer.

To view the full press release, visit: https://ibn.fm/wj9TN

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

• NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
• SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
• RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Tuesday's trading session at $0.335, up 39.4671%, on 126,309,406 volume. The average volume for the last 3 months is 3,423,936 and the stock's 52-week low/high is $0.2027/$3.89.

Recent News

• Calidi Biotherapeutics Inc. (NYSE American: CLDI) - InvestorNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform 
• Study Discovers Genetic Mutation that Makes Solid Tumors Unresponsive to Immunotherapy
• BioMedNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN)

The QualityStocks Daily Newsletter would like to spotlight SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN).

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) announced that its 7.2 MW Hoadley Hill Road ground-mount solar project in upstate New York has cleared the Coordinated Electric System Interconnection Review (CESIR), a major regulatory milestone. The project, which will power approximately 850 homes through New York's grid, is backed by the state's VDER compensation mechanism and may qualify for up to US$0.395/W DC in NYSERDA NY-Sun incentives. Structured as a community solar project, it offers residents and businesses bill credits without on-site installations. With over 100 MW built and a pipeline exceeding 1 GW, SolarBank is accelerating permitting and financing to move into construction, supporting New York's goal of 6 GW installed solar by 2025.

To view the full press release, visit https://ibn.fm/ZvEKF

Renewable energy is the key to significantly reducing the world's reliance on fossil fuels, addressing runaway climate change, and arresting human-caused atmospheric heating. As countries continue to deploy wind, solar, hydropower, and other renewable energy sources, we will eventually stop relying on forms of energy that pollute the world. Here are some of the unspoken benefits of transitioning to renewables. Notable improvements in public health. Internal combustion engine (ICE) cars, power plants, and factories all contribute to air and water pollution. Transitioning these industries to renewable energy can reduce cases of asthma, hospitalizations, and premature death that are related to lung and heart disease. These conditions can be caused by air and water pollution and they often occur at higher rates in regions with more pollution. Renewables can also help to stabilize energy prices and make electricity more affordable. As fossil fuels are quite susceptible to geopolitical volatility, energy prices are often affected by geopolitics and rarely maintain stability. On the other hand, renewables like wind and solar rely on free inputs (wind and solar energy) and are much cheaper to operate compared to fossil fuel-fired power plants, allowing them to sell energy at low and stabilized prices. When paired with energy storage, renewables can be counted on to provide a constant and reliable supply of affordable energy. Fortunately, the number of companies like SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) that are focused on bringing innovative renewable energy solutions to the market are increasing. As the uptake of those products ramps up, communities around the world could enjoy more of the additional benefits of switching to renewable energy sources.

SolarBank Corporation (NASDAQ: SUUN) (CSE: SUNN) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the United States. The company is committed to advancing the transition to sustainable energy by offering end-to-end services that include project origination, financing structuring, engineering, procurement, construction, and long-term operations and maintenance. SolarBank focuses on delivering innovative energy solutions through solar photovoltaic systems, battery energy storage systems (BESS), and electric vehicle (EV) charging infrastructure.

With a vision to provide scalable and reliable clean energy solutions, SolarBank has established itself as a leader in the renewable energy market by cultivating partnerships with utilities, commercial and industrial entities, municipalities, and residential customers. Its vertically integrated business model allows for optimized efficiency, cost management, and returns across diverse markets in North America. This end-to-end approach ensures greater control over project quality, costs, and operational outcomes, strengthening its competitive position.

Driven by a mission to create a greener future, SolarBank manages a robust portfolio of projects, including more than 100 megawatts (MW) of developed capacity and a pipeline exceeding one gigawatt (GW). The company’s commitment to sustainability and innovation makes it a recognized player in the renewable energy sector.

SolarBank has offices in Toronto, Ontario and New York.

Projects

SolarBank boasts an impressive and diverse portfolio of renewable energy initiatives that underline its leadership in the clean energy space. In the U.S., the company has over 250 MW of solar projects under development, principally in New York, focusing on community solar farms and commercial and industrial installations. Notably, SolarBank is developing several community solar projects in upstate New York, which will deliver clean energy to local residents and small businesses. Community solar projects, which are a cornerstone of SolarBank’s portfolio, provide scalable solutions for renters, homeowners, and small businesses to access affordable renewable energy, driving localized energy independence and economic savings.

In Canada, SolarBank has been a significant participant in Ontario’s Feed-in-Tariff program, where it has secured contracts for close to 200 MW of capacity. Its current management includes 70 solar power projects, totaling 28.8 MW of operational solar assets. The company’s expertise extends to the development and ownership of battery energy storage systems and EV charging stations, further diversifying its portfolio.

The company’s vertically integrated approach spans the entire project lifecycle, from initial site acquisition and grid interconnection to long-term operation and maintenance services. This ensures seamless execution and high-quality outcomes, providing value to stakeholders and supporting the transition to a clean energy future.

Market Opportunity

SolarBank operates within a growing renewable energy market driven by global demand for sustainable power solutions. In North America, favorable policies such as the Inflation Reduction Act in the United States and Canada’s investments in green technologies provide a robust foundation for renewable energy adoption. Solar PV installations and battery energy storage systems are at the forefront of this expansion, addressing energy reliability and grid stability while reducing carbon emissions.

The North American solar PV market was valued at $25.02 billion in 2019 and is projected to reach $120.74 billion by 2027, growing at a compound annual growth rate (CAGR) of 21.7% from 2020 to 2027. Likewise, the global BESS market is expected to expand from $7.8 billion in 2024 to $25.6 billion by 2029, at a CAGR of 26.9%, as reported by MarketsandMarkets. These trends are driven by the increasing integration of renewable energy sources, the need for grid resilience, and declining technology costs.

SolarBank’s operations have it well-positioned to capitalize on these opportunities. With a development pipeline exceeding one gigawatt (GW), the company is focused on meeting growing demand in community and commercial solar sectors. Decentralized energy solutions, such as virtual net metering and behind-the-meter systems, further enhance SolarBank’s market potential by addressing the critical need for flexible, cost-effective, and sustainable energy infrastructure. By leveraging its vertically integrated model and diversified portfolio, SolarBank stands as a key player in driving the renewable energy transition.

Leadership Team

Dr. Richard Lu, MD, MSc., MHSc., MBA, serves as President and CEO of SolarBank, bringing over 25 years of global energy experience. His leadership has been instrumental in advancing the company’s strategic initiatives across North America, Europe, and Asia, with a focus on renewable energy development and operational excellence.

Sam Sun, MBA, is the Chief Financial Officer of SolarBank. A Chartered Professional Accountant with more than 15 years of expertise in corporate finance, Mr. Sun has overseen financial strategies and internal controls across the cleantech, manufacturing, and mining sectors in Canada, the U.S., and China.

Andrew van Doorn, PE, serves as Chief Operating Officer, with nearly three decades of experience in engineering and construction. Mr. van Doorn has successfully led projects totaling over 200 MW of solar capacity and is a former Chairman of the Canadian Solar Industries Association.

Tracy Zheng, MBA, Chief Development Officer, has over 25 years of experience in brand marketing, business development, and solar project operations. She has spearheaded sales initiatives, conducted feasibility studies, and negotiated key partnerships that drive SolarBank’s growth.

Matt Wayrynen, Executive Chairman and Director, has a background in resource company management, venture capital, and mergers and acquisitions. Under his leadership, Solar Flow-Through Funds, where Mr. Wayrynen acted as CEO, was acquired by SolarBank, enhancing its asset portfolio and growth prospects.

---

Forward Looking Statements

This report contains forward-looking statements and forward-looking information ‎within the meaning of Canadian securities legislation (collectively, “forward-looking ‎statements”) that relate to the Company’s current expectations and views of future events. ‎Any statements that express, or involve discussions as to, expectations, beliefs, plans, ‎objectives, assumptions or future events or performance (often, but not always, through the ‎use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will ‎continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, ‎‎”projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be ‎forward-looking statements and may involve estimates, assumptions and uncertainties ‎which could cause actual results or outcomes to differ materially from those expressed in ‎such forward-looking statements. In particular and without limitation, this report ‎contains forward-looking statements pertaining to the Company’s expectations regarding its industry trends and overall market growth of the data center market; the Company’s expansion into the data center market, including its pursuit of opportunities as a developer, owner, and strategic partner in data center infrastructure; supporting the demand for high-performance, sustainable energy solutions within the sector; details of the company’s business plan including development of solar power projects, battery storage projects and EV charging projects; the completion of any contracts for, or construction of, any data center, solar power, battery storage or EV projects; the receipt of interconnection approval, permits and financing to be able to construct projects; the receipt of incentives for projects; and the size of the Company’s development pipeline. No assurance ‎can be given that these expectations will prove to be correct and such forward-looking ‎statements included in this report should not be unduly relied upon. These ‎statements speak only as of the date of this report.‎

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. In making the forward looking statements included in this report, the Company has made various material assumptions, including but not limited to: obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and services offered by the Company’s competitors; that the Company’s current good relationships with its service providers and other third parties will be maintained; and government subsidies and funding for renewable energy will continue as currently contemplated. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Forward-‎Looking Statements” and “Risk ‎Factors” in the Company’s most recently completed Annual Information Form, and other public filings of the Company, which include: the Company may be adversely affected by volatile solar power market and industry conditions; the execution of the Company’s growth strategy depends upon the continued availability of third-party financing arrangements; the Company’s future success depends partly on its ability to expand the pipeline of its energy business in several key markets; governments may revise, reduce or eliminate incentives and policy support schemes for solar and battery storage power; general global economic conditions may have an adverse impact on our operating performance and results of operations; the Company’s project development and construction activities may not be successful; developing and operating solar projects exposes the Company to various risks; the Company faces a number of risks involving Power Purchase Agreements (“PPAs”) and project-level financing arrangements; any changes to the laws, regulations and policies that the Company is subject to may present technical, regulatory and economic barriers to the purchase and use of solar power; the markets in which the Company competes are highly competitive and evolving quickly; an anti-circumvention investigation could adversely affect the Company by potentially raising the prices of key supplies for the construction of solar power projects; foreign exchange rate fluctuations; a change in the Company’s effective tax rate can have a significant adverse impact on its business; seasonal variations in demand linked to construction cycles and weather conditions may influence the Company’s results of operations; the Company may be unable to generate sufficient cash flows or have access to external financing; the Company may incur substantial additional indebtedness in the future; the Company is subject to risks from supply chain issues; risks related to inflation; unexpected warranty expenses that may not be adequately covered by the Company’s insurance policies; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the renewable energy market; there are a limited number of purchasers of utility-scale quantities of electricity; compliance with environmental laws and regulations can be expensive; corporate responsibility may adversely impose additional costs; the future impact of any resurgence of COVID-19 on the Company is unknown at this time; the Company has limited insurance coverage; the Company will be reliant on information technology systems and may be subject to damaging cyberattacks; the Company may become subject to litigation; there is no guarantee on how the Company will use its available funds; the Company will continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that will dilute the current shareholders; and future dilution as a result of financings.

The Company undertakes no obligation to update or revise any ‎forward-looking statements, whether as a result of new information, future events or ‎otherwise, except as may be required by law. New factors emerge from time to time, and it ‎is not possible for the Company to predict all of them, or assess the impact of each such ‎factor or the extent to which any factor, or combination of factors, may cause results to ‎differ materially from those contained in any forward-looking statement. Any forward-‎looking statements contained in this report are expressly qualified in their entirety by ‎this cautionary statement.‎

SolarBank Corp. (NASDAQ: SUUN), closed Tuesday's trading session at $1.5, even for the day, on 627 volume. The average volume for the last 3 months is 564,170 and the stock's 52-week low/high is $1.23/$6.43.

Recent News

• SolarBank Corp. (Cboe CA: SUNN) (FSE: GY2) (NASDAQ: SUUN) - 5 Benefits of Using Renewable Energy That Aren't Commonly Talked About
• ESGBreaks - SolarBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Advances 7.2 MW New York Solar Project Following Key Regulatory Approval
• Report Calls for Accelerating Energy Storage System Deployments

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM)

The QualityStocks Daily Newsletter would like to spotlight Silvercorp Metals Inc. (TSX.V: SVM) (NYSE American: SVM).

Silvercorp Metals (NYSE American: SVM) (TSX: SVM) , a Canadian mining company producing silver, gold, lead, and zinc, delivered its strongest fourth-quarter performance to date. The company closed out fiscal 2025, ended March, with significant growth in both revenue and operating cash flow with results reflecting increased production volumes and stronger realized prices across the company's key metals. "Income from mine operations in the quarter climbed to $26.1 million, up from $13.0 million in Q4 Fiscal 2024. Silvercorp also increased capital investments in its core operations, spending $9.9 million in China and $3.1 million on its El Domo project in Ecuador during the quarter," reads a recent article. "Even after these investments, the company added cash to its balance sheet and reported cash and short-term investments of $369.1 million, up from $354.6 million at the end of December 2024. It also held a $70.9 million portfolio of equity investments and has access to a $175 million stream financing credit to support El Domo mine construction."

To view the full article, visit https://ibn.fm/L6ybz

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) is a Canadian mining company producing silver, gold, lead, and zinc, with a long history of profitability and growth. The company focuses on creating shareholder value by generating free cash flow from long-life mines, expanding through organic growth opportunities in China and Ecuador, and pursuing strategic mergers and acquisitions. Silvercorp has built a reputation as a low-cost producer with a commitment to responsible mining practices.

With over 18 years of operating experience, Silvercorp has developed a diversified portfolio of mining assets and investments in China, Ecuador, and Bolivia. The company leverages its expertise in exploration and operational efficiency to enhance the value of its projects while maintaining a strong balance sheet. Silvercorp’s disciplined approach to mine expansion and resource development ensures long-term sustainable growth.

The company’s mission is to build and operate profitable mines that generate sustainable economic, social, and environmental benefits for stakeholders. Silvercorp is committed to responsible mining, with a focus on environmental stewardship and community engagement.

The company is headquartered in Vancouver, Canada.

Portfolio

Silvercorp operates a diverse portfolio of producing mines, construction-stage projects, and exploration assets across multiple jurisdictions. The company focuses on optimizing production from existing operations while strategically advancing new projects to drive future growth.

• Ying Mining District (China) – The company’s flagship operation consists of several underground mines producing silver, gold, lead and zinc in concentrates. In fiscal 2025, Ying produced 6.9 million ounces of silver and 7,495 ounces of gold, along with lead and zinc by-products. Fiscal 2026 guidance calls for continued production growth as ongoing mine optimization efforts continue to bear fruit.
• GC Mine (China) – A silver-lead-zinc mine with a history of consistent production and ongoing resource expansion through drilling. While production dipped slightly in fiscal 2025, output is expected to increase in fiscal 2026.
• El Domo (Ecuador) – A fully-permitted, copper-gold project under construction. In April 2025, Silvercorp announced a detailed and fully-funded $240.5 million construction plan. Major contracts have been awarded and construction activities are underway, with commissioning expected by December 2026.
• Condor Project (Ecuador) – A gold exploration asset with significant resources. In May 2025, Silvercorp published an updated mineral resource estimate focusing on high-grade underground zones. A revised PEA is expected by the end of 2025, alongside continued permitting and community engagement efforts.
• Kuanping Project (China) – A permitted gold-lead-zinc satellite project north of Ying. Mine construction is underway and Kuanping will be an underground mine with ore to be milled at the Ying complex.
• BYP Mine (China) – A gold-lead-zinc project that operated previously and is now undergoing permitting as a gold mine.
• Bolivian Assets – Silvercorp holds a 28% stake in New Pacific Metals (TSX: NUAG, NYSE American: NEWP), providing indirect exposure to two world class silver projects: Silver Sand and Carangas.

Through its diversified portfolio, Silvercorp delivers exposure to operations generating growing cash-flow, as well as high-potential growth projects that will create long-term value for shareholders.

Market Opportunity

The global demand for silver, gold, and base metals remains strong, driven by industrial applications, investment demand, and renewable energy initiatives. Silvercorp is well positioned to capitalize on rising silver demand, particularly in China, where 80% of the world’s solar panels are manufactured—an industry heavily reliant on silver.

Ecuador’s mining sector is experiencing rapid growth, with government support for foreign investment and infrastructure improvements. Mining exports in the country surged from $275 million in 2018 to $3.3 billion in 2023, highlighting the sector’s increasing economic importance. Silvercorp’s El Domo and Condor projects are poised to become key contributors to Ecuador’s mining expansion.

Industry forecasts indicate continued growth in silver and base metal prices, benefiting producers with strong operational performance and cost controls. Silvercorp’s diversified asset base and low-cost production profile provide resilience against market fluctuations, positioning the company for long-term value creation.

Leadership Team

Rui Feng, Ph.D., Chairman & CEO, founded Silvercorp and has over 30 years of experience in mineral exploration and mining. He has been instrumental in leading the company’s strategic vision, transforming it into a profitable, low-cost silver producer with a diversified asset base. Under his leadership, Silvercorp has expanded its global footprint, acquiring and developing high-value mining projects across China, Ecuador, and Bolivia. Dr. Feng’s expertise in geology and resource development has contributed to major mineral discoveries, and his disciplined approach to capital allocation has positioned the company for long-term growth.

Derek Liu, MBA, CGA, CPA, Chief Financial Officer, brings over two decades of financial leadership experience in the mining sector, overseeing capital allocation, financial strategy, and risk management. He has played a crucial role in maintaining Silvercorp’s strong balance sheet and financial discipline, ensuring the company remains well-capitalized for organic growth and strategic acquisitions. His expertise in financial planning, compliance, and investor relations has supported Silvercorp’s continued profitability and operational efficiency in a competitive global mining landscape.

Lon Shaver, CFA, President, has extensive experience in corporate finance, equity research, and capital markets, providing strategic guidance on business development and investor relations. Before joining Silvercorp, he held senior roles in investment banking and asset management, where he advised mining companies on financing, mergers, and acquisitions. His deep understanding of capital markets and industry dynamics helps drive Silvercorp’s corporate growth initiatives, enhance shareholder value, and strengthen relationships with institutional investors and stakeholders.

Silvercorp Metals Inc. (NYSE American: SVM), closed Tuesday's trading session at $4.65, off by 4.1237%, on 5,589 volume. The average volume for the last 3 months is 7,608,432 and the stock's 52-week low/high is $2.87/$5.32.

Recent News

• Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) - MiningNewsBreaks - Silvercorp Metals Inc.'s (NYSE American: SVM) (TSX: SVM) Growing Portfolio, Strong Balance Sheet Drive Investor Appeal
• Silvercorp Metals Inc. (NYSE-A: SVM) (TSX: SVM) Reports Record Q4 Results and Strong Cash Flow for Fiscal 2025
• MiningNewsBreaks - Why Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) Is 'One to Watch'

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

University of Sydney researchers have, for the first time ever, targeted a malfunctioning protein in mice having symptoms akin to Parkinson's symptoms and successfully improved motor function in the mice. This breakthrough finding could open the door to finding a similar way to treat Parkinson's disease in humans. For more than 10 years, the team worked to establish the biological mechanisms which underpin Parkinson's. Their interest was in uncovering new ways to slow the progression of the disease or even treat it. In 2017, they published research documenting SOD1 protein abnormalities within the brain and showed that these abnormalities were present in the brain matter of individuals living with Parkinson's disease. Usually, SOD1 proteins play a protective role within the brain, but when one has Parkinson's, the proteins form clumps, triggering brain cell damage. The clumping is linked to malfunctions within these vital proteins. Just over a million people in the U.S. have Parkinson's disease and about 90,000 individuals are diagnosed with this condition annually. Finding effective ways to slow disease progression or reverse it would therefore have a positive impact on the lives of this growing section of the population. Enterprises like Clene Inc. (NASDAQ: CLNN) and others are focused on finding efficacious treatments that can treat this disease so that patients can get a reprieve from the grip of this condition. As more studies are conducted, breakthrough interventions are likely to be commercialized in the not-too-distant future. 

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $3.8, off by 1.8088%, on 2 volume. The average volume for the last 3 months is 115,263 and the stock's 52-week low/high is $2.2801/$6.96.

Recent News

• Clene Inc. (NASDAQ: CLNN) - Preclinical Study Finds a Way to Reverse Symptoms of Parkinson's in Mice 
• Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025
• Why Public Interest in Mitochondrial Function Testing is Growing

Massimo Group (NASDAQ: MAMO)

The QualityStocks Daily Newsletter would like to spotlight Massimo Group (NASDAQ: MAMO).

President Donald Trump's Big Beautiful Bill will put a definitive end to federal tax incentives for electric vehicle buyers. In its quest to undo most of the Biden administration's climate action-related policies, the Trump administration initially laid out a timeline for phasing out EV tax credits through 2025. However, the recently passed Big Beautiful Bill will effectively end the federal EV incentive on September 30th. According to the huge tax and spending cut measure, American drivers interested in purchasing an electric car will have three more months to subsidize the EV purchase using the $7,500 tax incentive. In a market where the average electric car is notably more expensive than a similar petrol or diesel-powered vehicle, this incentive has been critical to encouraging electric vehicle adoption. On average, an electric vehicle driver will save $7,700 in fueling costs over a decade and a half if they use both private and public chargers to recharge their vehicle. The amount of savings will, of course, vary based on factors such as location, the make of electric car, and where and when drivers charge their EVs. Entities like Massimo Group (NASDAQ: MAMO) are likely to study how the changes in federal policy could reshape market dynamics within the auto industry. 

Massimo Group (NASDAQ: MAMO) is a prominent manufacturer and distributor specializing in powersports vehicles and recreational watercraft. Established in 2009, the company has built a reputation for delivering value-packed utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), and on-road vehicles to both recreational enthusiasts and professionals in the agricultural sector. In 2020, Massimo expanded its offerings by launching Massimo Marine, dedicated to crafting high-quality watercraft with advanced designs and exceptional customer service.

Massimo Group is focused on sustainability. Its recent initiatives, including the introduction of the MVR Series of electric carts, highlight the company’s commitment to eco-friendly solutions that address growing consumer demand for sustainability in the powersports and marine industries.

The company’s manufacturing capabilities have also evolved significantly. Its expanded 376,000-square-foot facility in Garland, Texas, now features advanced automation, including a vehicle assembly robot line. This addition is expected to significantly enhanced production capacity and efficiency, enabling Massimo to scale its operations and better meet market demand.

Product Portfolio

Massimo Group’s product portfolio showcases its dedication to innovation and versatility. Its diverse lineup combines advanced features, sustainability, and value to meet the needs of a dynamic market.

• Massimo Motor: This category includes a wide range of UTVs, ATVs, go-karts, and mini-bikes designed for both recreational and practical applications. Notable recent additions include the T-Boss 1000 UTV, which combines rugged performance with advanced features, and the GKD 350 All-Terrain Go-Kart, a versatile two-seater ideal for various terrains. The Buck 550-6 Crew, a six-seater UTV, further expands this lineup, providing comfort and utility for families and light-duty users at an accessible price point.
• Massimo Marine: Specializing in pontoon and tritoon boats, this division emphasizes luxury and performance. A recent collaboration between Massimo and Vision Marine Technologies has introduced electric pontoon platforms, catering to consumers seeking eco-friendly watercraft for both commercial and recreational use.
• Massimo Electric: Reflecting the company’s commitment to sustainability, Massimo Electric focuses on low-speed electric vehicles (LSVs) tailored for diverse applications. Recent launches include the MVR 2X Golf Cart and MVR Cargo Max Utility Cart, which deliver advanced features and versatility for recreational users and professionals in industries like farming and groundskeeping.

By combining practicality with cutting-edge design, Massimo Group seeks to set the standard in the powersports and marine industries.

Market Opportunity

The global ATV and UTV market is experiencing robust growth, with North America projected to reach approximately $9.18 billion in 2024 and expand at a compound annual growth rate (CAGR) of 7.8% to $13.37 billion by 2029, according to Mordor Intelligence. Likewise, the U.S. electric UTV and ATV powertrain market is rapidly expanding. It was valued at $2.46 billion in 2022 and is expected to grow at a CAGR of 10.2%, reaching $5.18 billion by 2030, as reported by Grand View Research.

The pontoon boat market complements this growth, driven by increased interest in leisure and marine tourism. The market size exceeded $7.9 billion in 2022 and is projected to grow at a CAGR of 8.3% through 2032, according to Global Market Insights. Massimo Marine’s introduction of electric pontoon platforms through its Vision Marine partnership is expected to position the company to effectively address this growing market segment.

With strategic partnerships and an expanding dealer network, Massimo believes it is poised to penetrate deeper into domestic and international markets. The company’s service coverage currently includes over 2,800 retail locations, 600 motor service centers, and 5,500 marine service centers, ensuring robust support and accessibility for customers. This extensive distribution network underpins Massimo’s ability to capture market share and drive sustained growth.

Leadership Team

David Shan, Founder, Chairman, and CEO, established Massimo Motor in 2009 and Massimo Marine in 2020. He has led the company through significant growth phases, including the development of diverse product lines and its public listing. Shan holds a bachelor’s degree in international trade from Qingdao Ocean University of China.

Dr. Yunhao Chen, CPA, serves as the company’s Chief Financial Officer, bringing extensive experience in capital markets, financial reporting, and corporate governance since her appointment in May 2023. She holds a Ph.D. in Accounting and an MBA in Finance from the University of Minnesota.

Michael Smith, Vice President, joined Massimo in 2019 and played a pivotal role in launching Massimo Marine. With a strong background in powersports retail and product innovation, he is dedicated to driving new product development. Smith studied International Business and Marketing at the University of California, San Diego.

Massimo Group (NASDAQ: MAMO), closed Tuesday's trading session at $2.44, off by 1.6129%, on 5 volume. The average volume for the last 3 months is 26,563 and the stock's 52-week low/high is $1.839/$4.6599.

Recent News

• Massimo Group (NASDAQ: MAMO) - Octopus, BYD Collaborate to Usher in EV and Charging Bundle for Motorists 
• BYD Ships Thousands of Electric Vehicles to Brazil Ahead of Tariff Implementation 
• Electric Vehicle Sales are Rebounding in Europe

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Tuesday's trading session at $1.22, up 8.9286%, on 12,282 volume. The average volume for the last 3 months is 2,137,257 and the stock's 52-week low/high is $1.09/$14.8299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar
• InvestorNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance
• Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF)

The QualityStocks Daily Newsletter would like to spotlight Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF).

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) is a Canadian mine development and exploration company advancing a portfolio of gold and silver assets in Nevada’s Walker Lane, one of the world’s most productive and mining-friendly regions. Through its U.S. subsidiaries, the company controls four gold and silver properties in Nevada, three of which are 100%-owned and one controlled via a low-cost option to acquire full ownership. With a clear near-term path to production, Lahontan is focused on unlocking oxide gold and silver value from past-producing, infrastructure-rich projects.

The company’s mission is to responsibly develop and expand its oxide resources while minimizing capital intensity and maximizing economic returns. Leveraging a strong technical team with a track record of advancing projects and building mines, Lahontan is focused on growing gold and silver resources and hitting permitting milestones across multiple sites. Its strategy prioritizes scalability, efficiency, and timely value realization for shareholders.

By maintaining full project ownership and a capital-light development model, Lahontan Gold is positioned to rapidly transition from development to production.

The company is headquartered in Toronto, Ontario.

Projects

Santa Fe Mine

The 26.4 km² Santa Fe Mine is Lahontan’s flagship asset and core development priority. A past-producing open-pit, heap-leach gold and silver operation, Santa Fe historically yielded more than 359,000 ounces of gold and 702,000 ounces of silver between 1988 and 1995. The site benefits from established infrastructure—including power, water, and road access—and more than 79% of its known resources are unencumbered by royalties.

A 2024 NI 43-101 resource estimate outlines 1.54 million ounces of gold equivalent (AuEq) in the Indicated category and 0.41 million ounces Inferred, all pit-constrained. Oxide resources average among the highest grades in the state and are distributed across five known deposits. A 2025 Preliminary Economic Assessment (PEA) projects strong economic returns, including an after-tax NPV5% of $200 million, a 34.2% internal rate of return (IRR), and average annual production of approximately 50,000 ounces AuEq over an eight-year mine life.

Permitting is well underway for both the Exploration and Mine Plans of Operation, covering over 12 km² and more than 700 drill holes. The company is targeting construction permits in late 2026 and continues to pursue oxide resource expansion and metallurgical optimization, particularly within the Slab-Calvada corridor.

West Santa Fe

West Santa Fe lies just 13 kilometers from the flagship and is being explored as a potential satellite operation. The project is defined by a shallow, oxide-dominant gold-silver system with a conceptual target of 0.5 to 1.0 million ounces AuEq based on historic drilling and recent surface sampling, which returned up to 2.61 g/t Au and 899 g/t Ag (14.6 g/t AuEq). A 6,300-meter Phase One reverse circulation drill program is scheduled for 2025 to validate historical data and support a maiden resource estimate. Development is streamlined under a low-cost option agreement and a rapid permitting path via Notice of Intent.

Moho and Redlich

The Moho and Redlich projects provide additional longer-term upside within Lahontan’s portfolio. Moho features high-grade, oxidized epithermal veins with historic production at grades of 20–25 g/t Au and 300 g/t Ag. A 2019 core drill program confirmed the presence of high-grade mineralization at depth. Redlich, located along trend from the historic Candelaria silver mine, hosts disseminated Ag mineralization in epithermal veins and hydrothermal breccias but remains untested by drilling. While no near-term programs are currently disclosed, both assets represent future exploration optionality.

Market Opportunity

Lahontan Gold operates in Nevada, consistently ranked the top global mining jurisdiction by the Fraser Institute due to its transparent permitting process, legal stability, and established infrastructure. Nevada produces over 4.5 million ounces of gold annually, generating approximately $9 billion in value, and ranks fifth globally in total gold production.

According to the World Gold Council, total gold demand in Q1 2025 reached 1,206 tonnes, up 1% year-over-year, marking the strongest first quarter since 2016. Central banks added 244 tonnes to reserves, a slight slowdown from the prior quarter but well within the strong buying range observed over the past three years. Meanwhile, silver demand is supported by strong industrial usage in solar panels, electric vehicles, and semiconductors, with long-term deficits forecast in the physical silver market.

With macro-driven demand for gold, technology-driven silver consumption, and strong institutional buying across both metals, Lahontan is uniquely positioned to capitalize through its portfolio of oxide-focused projects in a top-tier jurisdiction—offering near-term production potential and longer-term resource expansion.

Leadership Team

Kimberly Ann, Founder, CEO, President & Executive Chair, is a veteran mining executive with a track record of founding and scaling junior resource companies. She has raised over $210M in financing and led the $340M buyout of Prodigy Gold. Her prior roles include CFO of PPX Mining and founder of Latin America Resource Group, which merged with Carube Copper to form C3 Metals.

Brian Maher, Founder and VP of Exploration, is an economic geologist with more than 45 years of experience. He previously led Prodigy Gold as CEO, where he helped develop the Magino gold project before its $341M acquisition. His career includes senior roles at ASARCO, Hochschild Mining, and PPX Mining, where he oversaw exploration and production in the Americas.

John McNeice, Chief Financial Officer, is a Chartered Professional Accountant with three decades of experience in public company reporting. He has served as CFO for seven public resource companies and played a key role in Ur-Energy Inc.’s TSX IPO and $150M in financings. He also serves as CFO for Gold79 Mines, C3 Metals, and Northern Graphite Corp.

Lahontan Gold Corp. (OTCQB: LGCXF), closed Tuesday's trading session at $0.07285, up 4.0714%, on 126,583 volume. The average volume for the last 3 months is 1,010,580 and the stock's 52-week low/high is $0.0143/$0.09049.

Recent News

• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) - Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Drives Metallurgical Testing to Unlock Santa Fe Value
• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Set to Capitalize on Potential of Nevada's Walker Lane
• RockBreaks - As Gold Continues to Shine, Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Offers Compelling Investment Opportunity

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $0.9127, up 3.2933%, on 2,901 volume. The average volume for the last 3 months is 217,150 and the stock's 52-week low/high is $0.7303/$82.5.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - TinyGemsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar 
• BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit
• Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis